Superluminal Raises $60 Million to Move a Biased MC4R Agonist into Phase I

Company: Superluminal Medicines · Round: $60 Million Series B · Lead Investor: BVF Partners · Lead Asset: Biased MC4R Agonist (Oral) · Date: September 3, 2026 Summary Superluminal Medicines closed an oversubscribed $60 million Series B led by BVF Partners, with new participation from Deep…